RECHERCHE :   Tumeurs solides avancées
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
BMS CA022-001: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
Tumeurs solides avancées
I, II
CHUV
MEDIMMUNE D6770C00001: A phase 1, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumors
Tumeurs solides avancées/ Adénocarcinome canalaire pancréatique métastatique (Part3)/ Carcinome épidermoïde du poumon avancé - Adénocarcinome canalaire pancréatique avancé (Pharmacodynamique)
I
CHUV
AMGEN 20140318 - T-VEC intrahepatic: A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected into Liver Tumors Alone and in Combination With Systemic Pembrolizumab
Tumeur du foie non opérable (HCC) ou non-HCC
I, II
CHUV, HUG
BMS CA224-020 - A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Mélanome, cancer de la vessie
I
CHUV
BMS CA224-048: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
Tumeurs solides (Mélanome, Cancer du poumon non à petites cellules (NSCLC))
I, II
CHUV
MK7339-002 : A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
II
HUG
MK7902-005: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors
Selected solid tumors previously treated
II
HUG
MVX-ONCO-1: An open phase I clinical study assessing safety and tolerability of MVX-ONCO-1 in patients with solid tumor who are not/not any longer amenable to standard therapy
Immunothérapie pour tumeur solide avancée après traitements standards
I
HUG
CHUV-DO-0018-NeoTIL-2019: Pilot Study to Assess the Feasibility, Safety and Efficacy of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes Enriched for Tumor Antigen Specificity (NeoTIL) in Advanced Solid Tumors.
Tumeurs solides
I
CHUV
Nivo-71: A registry for patients with progressing metastatic solid tumor infiltrated by CD8+ T cells and receiving nivolumab off-label in the Romand Network of Oncology (RRO)
Tumeurs solides
registre
CHUV
PH- IL12L19L19-01/19: A phase I study to evaluate safety and early signs of efficacy of the human monoclonal antibody-cytokine fusion protein IL12-L19L19.
Advanced or metastatic carcinomas and diffuse large B-cell lymphoma
I
HUG
PT-112-103-PAVE-1: A Phase 1b/2a Dose Escalation and Confirmation Study of PT- 112 in Advanced Solid Tumors in Combination with Avelumab
carcinome urothélial métastatique ou localement avancé ou un cancer du poumon non à petites cellules
I
CHUV
RACIN, A phase I study of the combination of nivolumab associated with low-dose radiation, aspirin/ celecoxib and either ipilimumab or low-dose cyclophosphamide, followed by nivolumab maintenance, in patients with advanced, TIL-negative solid tumors
Tumeurs solides
I
CHUV